C. Bolan

发表

Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy.

Simeon I. Taylor, P. Gorden, S. Leitman, 2002, The Journal of clinical endocrinology and metabolism.

Streptococcus agalactiae sepsis after transfusion of a plateletpheresis concentrate: benefit of donor evaluation

W. T. Stevens, D. Stroncek, S. Leitman, 2006, Transfusion.

Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non‐myeloablative haematopoietic cell transplantation

J. P. McCoy, R. Srinivasan, J. McCoy, 2005, British journal of haematology.

Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility

A. Barrett, R. Childs, S. Leitman, 2001, British journal of haematology.

Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

J. Tisdale, M. Hsieh, Carla Saenz, 2009, Cytotherapy.

Hemochromatosis subjects as allogeneic blood donors: a prospective study

H. Klein, S. Leitman, H. Klein, 2003, Transfusion.

Blood Component and Pharmacologic Therapy for Hemostatic Disorders

H. Klein, C. Bolan, 2013 .

Chapter 27 – Blood Component and Pharmacologic Therapy of Hemostatic Disorders

H. Klein, C. Bolan, 2007 .

Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.

D. Porter, K. Ballen, D. Confer, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Placebo‐controlled study of intravenous magnesium supplementation during large‐volume leukapheresis in healthy allogeneic donors

Judith M Starling, S. Leitman, R. Wesley, 2005, Transfusion.

Correction: Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings

R. Grounds, R. M. Grounds, C. Bolan, 2005, Critical Care.

Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings

R. M. Grounds, C. Bolan, 2005, Critical care.

Left ventricular systolic function during stress echocardiography exercise in subjects with asymptomatic hereditary hemochromatosis.

Kevin P. Smith, V. Sachdev, M. Waclawiw, 2006, The American journal of cardiology.

Changes in Exercise Capacity in Subjects with Cardiac Asymptomatic Hereditary Hemochromatosis During a Follow-Up After 5 yrs

Kevin P. Smith, R. Arena, M. Waclawiw, 2012, American journal of physical medicine & rehabilitation.

Randomized placebo‐controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects

R. Wesley, S. Leitman, R. Wesley, 2003, Transfusion.

Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.

A. Barrett, M. Bishop, J. Tisdale, 2008, Blood.

Pharmacologic agents in the management of bleeding disorders

B. Alving, C. Bolan, B. Alving, 1990, Transfusion.

Changes in left ventricular diastolic function of asymptomatic hereditary hemochromatosis subjects during five years of follow-up.

V. Sachdev, C. Brenneman, M. Waclawiw, 2011, The American journal of cardiology.

CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?

J. Byrd, E. Estey, R. Howard, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemolytic anemia and cancer.

R. Weiss, L. Diehl, C. Bolan, 1996, Cancer treatment reviews.

Analysis of PBPC cell yields during large‐volume leukapheresis of subjects with a poor mobilization response to filgrastim

S. Leitman, C. Bolan, Y. Yau, 2003, Transfusion.

blood stem cell mobilization in an ethnically diverse population Donor demographic and laboratory predictors of allogeneic peripheral

M. Bishop, J. Tisdale, R. Childs, 2013 .

Exercise capacity of cardiac asymptomatic hereditary hemochromatosis subjects.

Kevin P. Smith, R. Arena, M. Waclawiw, 2007, Medicine and science in sports and exercise.

Transfusion‐associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus

G. Illei, J. Tisdale, D. Boumpas, 2003, Transfusion.

Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis.

V. Sachdev, M. Waclawiw, S. Leitman, 2006, The American journal of cardiology.

Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation.

A. Barrett, D. Stroncek, R. Childs, 2001, Blood.

Human ehrlichiosis: a newly recognized tick-borne disease.

A. Artenstein, C. Bolan, D. P. Goldman, 1992, American family physician.

Pediatric large‐volume leukapheresis: a single institution experience with heparin versus citrate‐based anticoagulant regimens

C. Mackall, H. Malech, S. Leitman, 2004, Transfusion.

Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors.

S. Leitman, C. Bolan, 2002, Blood.

Prospective evaluation of cell kinetics, yields and donor experiences during a single large‐volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells

A. Barrett, R. Childs, E. Read, 2003, British journal of haematology.

Pharmacology and mechanism of action of ancrod: potential for inducing thrombosis.

B. Alving, C. Bolan, T. Reid, 1992, Blood.

The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation.

K. Ballen, R. Hartzman, N. Kernan, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF

J. P. McCoy, N. Geller, J. Joo, 2013, Journal of Immunology.

Plerixafor Compared with G-CSF Alloreactivity of T Cells Mobilized with Expression Profiles, and In Vivo Differences in the Phenotype, Cytokine Gene

J. P. McCoy, C. Dunbar, Susan Wong, 2013 .

Massive transfusion and nonsurgical hemostatic agents

J. Perkins, A. Cap, B. Weiss, 2008, Critical care medicine.

Role of plasminogen activator inhibitor-1 in promoting fibrin deposition in rabbits infused with ancrod or thrombin.

T. Reilly, B. Alving, C. Bolan, 1993, Blood.

Clinical guide to ABO-incompatible allogeneic stem cell transplantation.

E. Gehrie, B. Savani, Garrett S. Booth, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.

Jonathan D. Powell, Griffin P. Rodgers, J. Powell, 2009, The New England journal of medicine.

Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program.

T. Price, C. Karanes, C. Bolan, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donation activities and product integrity in unrelated donor allogeneic hematopoietic transplantation: experience of the National Marrow Donor Program.

R. Hartzman, Rebecca Miller, C. Bolan, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

NK Cell KIR Ligand Mismatches Influence Engraftment Following Combined Haploidentical and Umbilical Cord Blood (UCB) Transplantation In Patients With Severe Aplastic Anemia (SAA)

D. Stroncek, R. Childs, S. Leitman, 2013 .

Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

N. Geller, H. Hedlin, R. Srinivasan, 2007 .

Synchronous diffuse well-differentiated lymphocytic lymphoma and gastric adenocarcinoma presenting as splenomegaly and iron deficiency anemia.

C. Bolan, J. Redmond, L. Fink, 1990, The American journal of gastroenterology.

AMD3100 Mobilized Apheresis Products Are Rich in T-Cells That Do Not Undergo a Th-2 Type Cytokine Polarization: Implications for Allografting.

J. P. McCoy, R. Childs, Yoshiyuki Takahashi, 2005 .

A Comparison of Apheresis Cell Content Collected from the Same Donors Mobilized with Granulocyte Colony Stimulating Factor (G-CSF) Vs. a Single Injection of AMD3100.

R. Srinivasan, A. Barrett, R. Childs, 2004 .

Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

N. Geller, R. Srinivasan, R. Childs, 2004 .